Literature DB >> 20458250

Dual source dual energy MDCT: comparison of 80 kVp and weighted average 120 kVp data for conspicuity of hypo-vascular liver metastases.

Emma Robinson1, James Babb, Hersh Chandarana, Michael Macari.   

Abstract

PURPOSE: To determine whether liver metastases conspicuity is improved at 80 kVp when compared with weighted average (WA) simulated 120 kVp data using dual source dual energy CT.
METHODS: A total of 11 patients with 44 hypo-vascular liver metastases underwent contrast enhanced Dual Energy CT (DECT). In all cases the subject's abdominal diameter measured <or=35 cm. Data were reconstructed as a WA of the 140 kVp and 80 kVp acquisitions (simulating 120 kVp) and as a pure 80 kVp data set. A region of interest cursor was placed within the metastasis and adjacent normal parenchyma and attenuation differences and contrast to noise ratios (CNR) were calculated for the metastases at 80 kVp and on the WA acquisition. A mixed model 2-way analysis of variance was used to test whether the attenuation difference between metastases and normal liver was higher at 80 kVp than 120 kVp. An exact Wilcoxon matched-pairs signed rank test was used to test whether CNR was higher at 80 kVp. Cases were retrospectively reviewed to determine whether lesions could be seen on only one or both data sets. As the 80 kVp tube has a smaller detector than the 140 kVp tube, we also noted whether any of the liver lesions were not included on the 80 kVp dataset. Two radiologists in consensus evaluated the 80 kVp data and WA data and subjectively rated hepatic metastases conspicuity on a 4 point scale; with 1 being excellent, 2 good, 3 poor, and 4 not seen.
RESULTS: The mean size of the metastases was 2.6 cm. The mean +/- SD of the attenuation difference between the metastases and the normal liver was 78.37 +/- 24.6 at 80 kVp and 56.89 +/- 17.9 at 120 kVp. The mean difference in attenuation was significantly higher at 80 kVp (P < 0.001). In 2 cases, a metastases was only seen at 80 kVp. The difference between 80 and 120 kVp in terms of CNR was statistically significant (P = 0.042). In one patient, 11 lesions were not included in the smaller field of view of the 80 kVp detector. The conspicuity scores were rated as significantly better at 80 kv than at 120 kVp (P < 0.0001).
CONCLUSION: When compared with 120 kVp data, pure 80 kVp data acquired from a dual source dual energy MDCT scanner demonstrates greater attenuation differences and improved contrast to noise between metastatic disease and normal liver.

Entities:  

Mesh:

Year:  2010        PMID: 20458250     DOI: 10.1097/RLI.0b013e3181dfda78

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  21 in total

1.  Impact of model-based iterative reconstruction on low-contrast lesion detection and image quality in abdominal CT: a 12-reader-based comparative phantom study with filtered back projection at different tube voltages.

Authors:  André Euler; Bram Stieltjes; Zsolt Szucs-Farkas; Reto Eichenberger; Clemens Reisinger; Anna Hirschmann; Caroline Zaehringer; Achim Kircher; Matthias Streif; Sabine Bucher; David Buergler; Luigia D'Errico; Sebastién Kopp; Markus Wilhelm; Sebastian T Schindera
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

2.  Noise-reducing algorithms do not necessarily provide superior dose optimisation for hepatic lesion detection with multidetector CT.

Authors:  K L Dobeli; S J Lewis; S R Meikle; D L Thiele; P C Brennan
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

3.  "Sweet spot" for endoleak detection: optimizing contrast to noise using low keV reconstructions from fast-switch kVp dual-energy CT.

Authors:  Katherine E Maturen; Ravi K Kaza; Peter S Liu; Leslie E Quint; Shokoufeh H Khalatbari; Joel F Platt
Journal:  J Comput Assist Tomogr       Date:  2012 Jan-Feb       Impact factor: 1.826

Review 4.  Recent developments of dual-energy CT in oncology.

Authors:  David Simons; Marc Kachelriess; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2014-01-09       Impact factor: 5.315

5.  Can Realistic Liver Tissue Surrogates Accurately Quantify the Impact of Reduced-kV Imaging on Attenuation and Contrast of Parenchyma and Lesions?

Authors:  Andre Euler; Justin Solomon; Paul F FitzGerald; Ehsan Samei; Rendon C Nelson
Journal:  Acad Radiol       Date:  2018-09-28       Impact factor: 3.173

Review 6.  [Modern CT and PET/CT imaging of the liver].

Authors:  J Klasen; T A Heusner; C Riegger; D Reichelt; J Kuhlemann; G Antoch; D Blondin
Journal:  Radiologe       Date:  2011-08       Impact factor: 0.635

7.  Hypodense liver lesions in patients with hepatic steatosis: do we profit from dual-energy computed tomography?

Authors:  Johanna Nattenmüller; Waldemar Hosch; Tri-Thien Nguyen; Stephan Skornitzke; Andreas Jöres; Lars Grenacher; Hans-Ulrich Kauczor; Christof M Sommer; Wolfram Stiller
Journal:  Eur Radiol       Date:  2015-05-17       Impact factor: 5.315

8.  Assessment of image quality and low-contrast detectability in abdominal CT of obese patients: comparison of a novel integrated circuit with a conventional discrete circuit detector at different tube voltages.

Authors:  A Euler; T Heye; M Kekelidze; G Bongartz; Z Szucs-Farkas; C Sommer; B Schmidt; Sebastian T Schindera
Journal:  Eur Radiol       Date:  2014-10-15       Impact factor: 5.315

9.  Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute.

Authors:  S T Laroia; Ajeet Singh Bhadoria; Yamini Venigalla; G K Chibber; Chagan Bihari; Archana Rastogi; S K Sarin
Journal:  Eur J Radiol Open       Date:  2016-07-20

10.  Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis.

Authors:  Antonio Bottari; Salvatore Silipigni; Maria Ludovica Carerj; Antonino Cattafi; Sergio Maimone; Maria Adele Marino; Silvio Mazziotti; Alessia Pitrone; Giovanni Squadrito; Giorgio Ascenti
Journal:  Radiol Med       Date:  2019-10-05       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.